【摘要】 目的 探讨多发性骨髓瘤病人血清可溶性细胞间黏附分子1(sICAM1)水平的变化及其临床意义。方法 采用酶联免疫吸附法(ELISA)测定38例多发性骨髓瘤病人治疗前后血清sICAM1水平，32例健康体检者作为对照组。结果 38例初诊多发性骨髓瘤病人血清sICAM1水平高于对照组(F=26.489,q=13.195,P<0.01)及化疗后有效组的30例病人(q=11.076,P<0.01)，其中15例病情进展病人血清sICAM1水平高于30例有效组病人(q=4.697,P<0.05)。Ⅲ期病人血清sICAM1水平明显高于Ⅱ期和Ⅰ期病人(F=8.559,q=3.167、6.674,P<0.05)。结论 血清sICAM1水平检测可对多发性骨髓瘤病人病情进展、疗效及预后判断提供依据。
【关键词】 多发性骨髓瘤;细胞间黏附分子1;酶联免疫吸附测定
DETECTION OF SERUM sICAM1 LEVES IN MULTIPLE MYELOMA AND ITS CLINICAL SIGNIFICANCE CUI ZHONGGUANG, WU CHUNMEI, WANG HONGYI, et al (Department of Hematology, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China); [ABSTRACT] Objective To explore the clinical significance of sICAM1 in patients with multiple myeloma (MM). Methods Serum sICAM1 was measured with enzyme linked immunosorbent assay (ELISA) in 38 patients with MM and 32 normal controls. Results Serum level of sICAM1 in MM patients elevated significantly compared with the normal controls (F=26.489,q=13.195,P<0.01) and 30 responsive patients after chemotherapy (q=11.076,P<0.01), in which, serum level ofsICAM1 in 15 progressing MM patients also higher than that of the responsive group (q=4.697,P<0.05), and that in stageⅢ patients was much higher than that of stages Ⅱ and Ⅰones (F=8.559;q=3.167,6.674;P<0.05). Conclusion The detection of serum sICAM1 can provide an evidence for prediction of the status, therapeutic effect and prognosis of patients with multiple myeloma.
[KEY WORDS] Multiple myeloma; Cell adhesion molecule; Enzymelinked immunosorbent assay
近年来对细胞黏附分子(AM)的研究显示，可溶性细胞间黏附分子1(sICAM1)对揭示恶性血液病病人的发病规律有重要意义[1]。关于多发性骨髓瘤(MM)病人血清sICAM1水平的变化，国内外少见文献报道。本研究通过对38例MM病人血清sICAM1水平在不同时期进行检测，进一步探讨其临床意义，为MM的病情进展、疗效及预后判断提供依据。现将结果报告如下。
1 对象与方法
1.1 研究对象
选择我院自2004年7月～2008年4月住院初诊MM病人38例(MM组)，男21例，女17例;年龄41～79岁，平均60.6岁。参照Durie的临床分期标准：Ⅰ期8例，Ⅱ期10例，Ⅲ期20例。38
[1] [2] [3] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 妇产科论文 >> 正文